Tatva Chintan Pharma Chem Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 13.2 pts more than Nifty Microcap 250 and 13.0 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Tatva Chintan Pharma Chem submitted its Q1 FY26 (quarter ended June 30, 2025) unaudited financial results along with the auditor's limited review report from NDJ & Co. (unmodified opinion). On a consolidated basis, revenue from operations rose to Rs 1,168.64 million from Rs 1,054.64 million in Q1 FY25, a growth of about 11% year-on-year. Profit after tax jumped sharply to Rs 66.51 million (EPS Rs 2.84) compared with Rs 10.30 million (EPS Rs 0.44) in the year-ago quarter, aided by an expanded operating margin. Standalone revenue was largely flat at Rs 1,076.48 million. Additionally, the board approved the re-appointment of the Managing Director, two Whole-time Directors, and three Independent Directors for fresh terms starting February 2026, and accepted the resignation of CFO Ashok Bothra effective August 30, 2025, citing personal and professional reasons.
The sharp jump in profit on decent revenue growth signals improving profitability and cost discipline, which is positive for shareholders, though the PAT surge partly reflects a low base. The CFO exit could create short-term uncertainty until a replacement is announced, while the director re-appointments ensure leadership continuity.